Skip to main content
Veterinary Medicines

RABISIN MULTI, injekcinė suspensija

Authorised
  • Rabies virus, strain G52, Inactivated

Product identification

Medicine name:
RABISIN MULTI, injekcinė suspensija
Active substance:
  • Rabies virus, strain G52, Inactivated
Target species:
  • Dog
  • Cat
  • Cattle
  • Sheep
  • Ferret
  • Horse
Route of administration:
  • Subcutaneous use
  • Intramuscular use

Product details

Active substance and strength:
  • Rabies virus, strain G52, Inactivated
    1.00
    international unit(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
    • Cat
    • Cattle
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Sheep
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Ferret
  • Intramuscular use
    • Dog
    • Cat
    • Horse
      • Meat and offal
        0
        day
    • Cattle
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Sheep
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Ferret
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AA02
Authorisation status:
  • Valid
Authorised in:
  • Lithuania
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health France
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • State Food And Veterinary Service
Authorisation number:
  • LT/2/11/2029/001
Date of authorisation status change:

Documents

RV2029.pdf

Lithuanian (PDF)
Published on: 28/06/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."